Park K - Search Results

1

Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.

Park K, Han S, Gwak GH, Kim HJ, Kim J, Kim KM. Park K, et al. Breast Cancer Res Treat. 2006 Aug;98(3):337-42. doi: 10.1007/s10549-006-9170-7. Epub 2006 Feb 24. Breast Cancer Res Treat. 2006. PMID: 16502015

2

E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide.

Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY. Han S, et al. Among authors: park k. Breast Cancer Res Treat. 2003 Nov;82(1):11-6. doi: 10.1023/B:BREA.0000003843.53726.63. Breast Cancer Res Treat. 2003. PMID: 14672398

3

c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers.

Park K, Kwak K, Kim J, Lim S, Han S. Park K, et al. Hum Pathol. 2005 Jun;36(6):634-9. doi: 10.1016/j.humpath.2005.04.016. Hum Pathol. 2005. PMID: 16021569

4

Comparison of CVF (Cyclophosphamide+Vinorelbine+5-Fluorouracil) and CMF (Cyclophosphamide+Methotrexate+5-Fluorouracil) Adjuvant Chemotherapy in Early Breast Cancer.

Gwak G, Park K, Shin E, Han S, Kim JY, Kim H, Kim YD, Kim HJ, Kim KW, Bae BN, Yang KH, Cho H, Park SJ. Gwak G, et al. Among authors: park sj, park k. J Breast Cancer. 2011 Sep;14(3):223-8. doi: 10.4048/jbc.2011.14.3.223. Epub 2011 Sep 29. J Breast Cancer. 2011. PMID: 22031805 Free PMC article.

5

Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer.

Park K, Han S, Kim JY, Kim HJ, Kwon JE, Gwak G. Park K, et al. J Breast Cancer. 2011 Dec;14(4):276-82. doi: 10.4048/jbc.2011.14.4.276. Epub 2011 Dec 27. J Breast Cancer. 2011. PMID: 22323913 Free PMC article.

6

Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer.

Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY. Han S, et al. Among authors: park k. J Surg Oncol. 2003 Aug;83(4):241-7. doi: 10.1002/jso.10268. J Surg Oncol. 2003. PMID: 12884237

7

Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray.

Park K, Kim J, Lim S, Han S, Lee JY. Park K, et al. Mod Pathol. 2003 Sep;16(9):937-43. doi: 10.1097/01.MP.0000086487.78558.7D. Mod Pathol. 2003. PMID: 13679458

8

Feasibility of concurrent adjuvant chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer.

Han S, Kim J, Sohn S, Kwak GH, Kim JY, Park K. Han S, et al. Among authors: park k. J Surg Oncol. 2007 Jan 1;95(1):45-50. doi: 10.1002/jso.20715. J Surg Oncol. 2007. PMID: 17192866

9

Comparison of 6 cycles versus 4 cycles of neoadjuvant epirubicin plus docetaxel chemotherapy in stages II and III breast cancer.

Han S, Kim J, Lee J, Chang E, Gwak G, Cho H, Yang KH, Park S, Park K. Han S, et al. Among authors: park s, park k. Eur J Surg Oncol. 2009 Jun;35(6):583-7. doi: 10.1016/j.ejso.2009.01.002. Epub 2009 Feb 5. Eur J Surg Oncol. 2009. PMID: 19195817 Clinical Trial.

10

Genomic change of chromosome 8 predicts the response to taxane-based neoadjuvant chemotherapy in node-positive breast cancer.

Han S, Park K, Shin E, Kim HJ, Kim JY, Kim JY, Gwak G. Han S, et al. Among authors: park k. Oncol Rep. 2010 Jul;24(1):121-8. Oncol Rep. 2010. PMID: 20514452

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

24,540 results

Search Page

Filters